** Shares of Arovella Therapeutics rise as much as 15.7% to A$0.203, their biggest intraday pct gain since Oct 11, 2024
** The biotech firm says it secured A$20 mln ($12.39 mln) placement funding to wrap up inaugural clinical trial of lymphoma, leukemia drug ALA-101
** Placement is at an issue price of A$0.17 per share, representing a 2.9% discount to last trade
** Stock hits its highest level since mid-November 2024
** Over 4.5 mln shares change hands, 5.3x the 30-day avg
** Stock rose 47.8% in 2024
($1 = 1.6139 Australian dollars)
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。